Drug intelligence / Profile preview

IOS-6071

Development stage: Preclinical
Lead developer: ImmunOs Therapeutics
Modality: Antibody-Based Therapeutics

Overview

IOS-6071 is a preclinical-stage antibody being developed by ImmunOs Therapeutics for the treatment of inflammatory diseases. It utilizes the company's proprietary HLA-based platform to target the HLA-E/NKG2A axis. By modulating the interaction between HLA-E and the inhibitory receptor NKG2A, IOS-6071 aims to regulate inflammatory immune responses. This approach leverages the natural role of HLA molecules in immune signaling to restore balance in autoimmune and inflammatory conditions.

Targets

HLA-E (Human leukocyte antigen-e)KLRC1 (Killer cell lectin-like receptor subfamily C member 1)

Beyond the preview

Go deeper on IOS-6071.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IOS-6071.

Explore the full profile